September 5, 2014
Bayer Yakuhin’s Nexavar (sorafenib), the world’s first molecular-targeted treatment for differentiated thyroid cancer, received an additional indication in June for the treatment of unresectable differentiated thyroid cancer in Japan. No effective treatment for refractory thyroid cancer has been available up...read more